(Q37385347)

20 August 2017

1 reference

title

Novel targets for antiretroviral therapy: clinical progress to date (English)

1 reference

20 August 2017

main subject

anti-retroviral agent

0 references

author

Mark Holodniy

series ordinal

2

1 reference

20 August 2017

Birgitt Dau

1

1 reference

20 August 2017

publication date

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

69

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

31-50

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200969010-00003

20 August 2017

exact match

0 references

cites work

Trials that matter: CD4+ T-lymphocyte count-guided interruption of antiretroviral therapy in HIV-infected patients

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200969010-00003

Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200969010-00003

Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro

21 January 2018

1 reference

12 December 2020

Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.

1 reference

12 December 2020

Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities.

1 reference

12 December 2020

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection

1 reference

12 December 2020

Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients

1 reference

12 December 2020

Maraviroc for previously treated patients with R5 HIV-1 infection

1 reference

12 December 2020

Gene transfer in humans using a conditionally replicating lentiviral vector

1 reference

12 December 2020

The Anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor

1 reference

12 December 2020

CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor

1 reference

12 December 2020

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

1 reference

12 December 2020

PEGylation of cyanovirin-N, an entry inhibitor of HIV

1 reference

12 December 2020

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

1 reference

12 December 2020

Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes

1 reference

12 December 2020

Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance

1 reference

12 December 2020

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

1 reference

12 December 2020

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

12 December 2020

Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy

1 reference

12 December 2020

Molecular and Clinical Epidemiology of CXCR4‐Using HIV‐1 in a Large Population of Antiretroviral‐Naive Individuals

1 reference

12 December 2020

Rational design of novel HIV-1 entry inhibitors by RANTES engineering

1 reference

12 December 2020

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults

1 reference

12 December 2020

Access denied? The status of co-receptor inhibition to counter HIV entry

1 reference

12 December 2020

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

1 reference

12 December 2020

Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor

1 reference

12 December 2020

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

1 reference

12 December 2020

Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.

1 reference

12 December 2020

Within you, without you: HIV-1 Rev and RNA export

1 reference

12 December 2020

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

1 reference

12 December 2020

Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.

1 reference

12 December 2020

Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains

1 reference

12 December 2020

HIV transmission and primary drug resistance.

1 reference

12 December 2020

Clinical protocol. A phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects.

1 reference

12 December 2020

Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice

1 reference

12 December 2020

Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20).

1 reference

12 December 2020

Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development.

1 reference

12 December 2020

Sensitivity of HIV type 1 primary isolates to human anti-CD40 antibody-mediated suppression is related to coreceptor use.

1 reference

12 December 2020

Baseline HIV type 1 coreceptor tropism predicts disease progression

1 reference

12 December 2020

CD4+ count-guided interruption of antiretroviral treatment

1 reference

12 December 2020

Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients

1 reference

12 December 2020

Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.

1 reference

12 December 2020

Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome

1 reference

12 December 2020

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

12 December 2020

The prevalence of antiretroviral drug resistance in the United States

1 reference

12 December 2020

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

12 December 2020

Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.

1 reference

12 December 2020

Knockdown of cellular RNA helicase DDX3 by short hairpin RNAs suppresses HIV-1 viral replication without inducing apoptosis

1 reference

12 December 2020

Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection

1 reference

12 December 2020

HIV entry inhibitors: mechanisms of action and resistance pathways

1 reference

12 December 2020

Integrase inhibitors to treat HIV/AIDS.

1 reference

12 December 2020

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

1 reference

12 December 2020

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

1 reference

12 December 2020

Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors

1 reference

12 December 2020

Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections

1 reference

12 December 2020

Carrageenan formulation prevents macrophage trafficking from vagina: implications for microbicide development

1 reference

12 December 2020

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

1 reference

12 December 2020

CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro

1 reference

12 December 2020

Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture.

1 reference

12 December 2020

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1

1 reference

12 December 2020

Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1.

1 reference

12 December 2020

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

1 reference

12 December 2020

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

1 reference

12 December 2020

Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide

1 reference

12 December 2020

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

1 reference

12 December 2020

Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team

1 reference

12 December 2020

Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs

1 reference

12 December 2020

Genetic therapies against HIV.

1 reference

12 December 2020

HIV entry inhibitors.

1 reference

12 December 2020

On the horizon: promising investigational antiretroviral agents

1 reference

12 December 2020

A historical sketch of the discovery and development of HIV-1 integrase inhibitors

1 reference

12 December 2020

HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.

1 reference

12 December 2020

10.2165/00003495-200969010-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

20 August 2017

1009379220

0 references

1 reference